In addition, Gardyan et al. pioneered the use of HLA-DRB1*03:01 and HLA-DRB1*04:01 transgenic mice to identify HLA class II-restricted CD4+T cell epitopes from the breast cancer antigen NY-BR-1, offering new targets for cancer immunotherapy [54]. This evidence concerns the gene HLA-DRB1 and cancer.